Verge Genomics appoints Dr. Andrew Allen to its Board as Independent Director

– USA, CA –  Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, today announced the appointment of Dr. Andrew Allen (M.D., Ph.D.) to its Board as an Independent Director, bringing the skills and perspective necessary to help the company drive growth.

Dr. Andrew Allen is President and CEO at Gritstone bio.

“We’re pleased to have Andrew with his extensive track record of success join our Board of Directors,” said Co-founder and CEO, Alice Zhang. “As we move towards the clinic and to our ultimate goal of bringing AI-discovered medicines to patients, Andrew’s expertise in both drug discovery and development will be highly beneficial.”

About Dr. Andrew Allen

A co-founder of Gritstone bio, a clinical-stage biotechnology company developing next-generation cancer and infectious disease immunotherapies using machine learning, Dr. Allen has served as President and CEO and a member of the company’s Board of Directors. Before Gritstone, Dr. Allen co-founded Clovis Oncology, Inc., or Clovis, and served as its EVP of Clinical and Preclinical Development and CMO. Previously, Dr. Allen was CMO at Pharmion Corporation, served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company.

He currently serves on the Board of Directors of TCR2 Therapeutics, Inc., Epizyme, Inc., and Sierra Oncology, Inc.

“I am pleased to be joining Verge’s board at a pivotal time in the company’s trajectory,” said Dr. Allen. “Verge is focusing on devastating neurological diseases, including ALS, where patients and their families are desperately waiting for a medical breakthrough that can help them. I look forward to working with the Verge team on advancing drug targets discovered through their all-in-human AI platform so we can get them to people with genetic diseases who need them. The use of translational biomarkers, and careful patient selection, to enable swift and informative early clinical trials is common in cancer therapy, and many of these approaches can be applied to the equally serious diseases that Verge aims to treat.”

Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology, and Medicine in London.

About Verge Genomics

Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning. Verge has created a proprietary all-in-human platform, featuring one of the field’s largest and most comprehensive databases of neurodegenerative patient genomic data. The company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson’s disease toward the clinic.

For more information: https://www.vergegenomics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.